IL209868A0 - Improved peptide mediators of cholesterol effluk - Google Patents

Improved peptide mediators of cholesterol effluk

Info

Publication number
IL209868A0
IL209868A0 IL209868A IL20986810A IL209868A0 IL 209868 A0 IL209868 A0 IL 209868A0 IL 209868 A IL209868 A IL 209868A IL 20986810 A IL20986810 A IL 20986810A IL 209868 A0 IL209868 A0 IL 209868A0
Authority
IL
Israel
Prior art keywords
effluk
cholesterol
improved peptide
peptide mediators
mediators
Prior art date
Application number
IL209868A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL209868A0 publication Critical patent/IL209868A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL209868A 2008-06-18 2010-12-09 Improved peptide mediators of cholesterol effluk IL209868A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7370808P 2008-06-18 2008-06-18
PCT/US2009/047694 WO2009155366A2 (en) 2008-06-18 2009-06-17 Improved peptide mediators of cholesterol efflux

Publications (1)

Publication Number Publication Date
IL209868A0 true IL209868A0 (en) 2011-02-28

Family

ID=41434685

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209868A IL209868A0 (en) 2008-06-18 2010-12-09 Improved peptide mediators of cholesterol effluk

Country Status (14)

Country Link
US (1) US8415293B2 (https=)
EP (1) EP2300038A4 (https=)
JP (1) JP2011525181A (https=)
KR (1) KR20110043597A (https=)
CN (1) CN102123722A (https=)
AU (1) AU2009260024A1 (https=)
BR (1) BRPI0915422A2 (https=)
CA (1) CA2727465A1 (https=)
CL (1) CL2010001445A1 (https=)
IL (1) IL209868A0 (https=)
MX (1) MX2010014003A (https=)
PE (1) PE20110106A1 (https=)
RU (1) RU2011101536A (https=)
WO (1) WO2009155366A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123173A1 (en) * 2010-04-28 2013-05-16 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2016044177A1 (en) * 2014-09-17 2016-03-24 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
JP2018528257A (ja) * 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーＰｅｐｔｉｎｏｖｏ Ｂｉｏｐｈａｒｍａ， ＬＬＣ 疎水性薬剤の効能を改善するための配合物
US11840707B2 (en) 2016-05-31 2023-12-12 Institut De Cardiologie De Montreal Co-culture system and method for in vitro assessment of reverse cholesterol transport
CN110294791B (zh) * 2019-06-13 2023-02-21 倪京满 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
CN111848742B (zh) * 2020-07-23 2021-03-23 南京医科大学 一种多肽及其制药用途
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2549529A1 (en) 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
CA2672131C (en) 2006-12-13 2016-06-07 The Regents Of The University Of California Potent and selective mediators of cholesterol efflux

Also Published As

Publication number Publication date
AU2009260024A1 (en) 2009-12-23
JP2011525181A (ja) 2011-09-15
KR20110043597A (ko) 2011-04-27
PE20110106A1 (es) 2011-03-02
WO2009155366A3 (en) 2010-04-22
EP2300038A4 (en) 2013-09-04
WO2009155366A2 (en) 2009-12-23
MX2010014003A (es) 2011-02-15
CN102123722A (zh) 2011-07-13
EP2300038A2 (en) 2011-03-30
BRPI0915422A2 (pt) 2017-06-27
US8415293B2 (en) 2013-04-09
US20110190196A1 (en) 2011-08-04
CL2010001445A1 (es) 2012-03-16
CA2727465A1 (en) 2009-12-23
RU2011101536A (ru) 2012-07-27

Similar Documents

Publication Publication Date Title
IL209868A0 (en) Improved peptide mediators of cholesterol effluk
EG25742A (en) Photobioreactor
ZA201006252B (en) Preparation of lenalidomide
GB0812712D0 (en) Improved endoscope
GB0913775D0 (en) Multispecific peptides
SG10201506935QA (en) Enzymatic process
GB2452358C (en) Preparation of bile acids.
IL212119A0 (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
GB0806595D0 (en) Recovery of stilbenoids
EP2346073A4 (en) PRE-ALIGNMENT SYSTEM
PL2171061T3 (pl) Preparat esterazy
GB0804721D0 (en) Enzyme
GB0809446D0 (en) Stage nacigation aid
GB0818328D0 (en) Novel enzyme
GB0814573D0 (en) Photobioreactors
GB0803628D0 (en) Enzyme
PL2278890T3 (pl) Kompozycje fitosteroli o zwiększonej dostępności biologicznej
GB0804722D0 (en) Enzyme
GB2459774B (en) Improved running bases
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
AU2008901947A0 (en) Treatment of Ores
GB0810742D0 (en) Enzyme
AU2009903383A0 (en) Clothes peg
GB0805873D0 (en) Permanent-magnet assembly